Live Breaking News & Updates on Eilean therapeutics

Stay updated with breaking news from Eilean therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

EILEAN THERAPEUTICS RECEIVES CLEARANCE TO INITIATE R/R AML TRIAL WITH LOMONITINIB, A SELECTIVE PAN-FLT3/IRAK4 INHIBITOR

EILEAN THERAPEUTICS RECEIVES CLEARANCE TO INITIATE R/R AML TRIAL WITH LOMONITINIB, A SELECTIVE PAN-FLT3/IRAK4 INHIBITOR
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Dover , Tasmania , Australia , Amy-burd , Human-research-ethics-committee , Ai-expert-systems-inc , Eilean-therapeutics , Prnewswire-eilean-therapeutics , Chief-executive-officer , Torrey-pines-investment , Expert-systems-inc ,

Expert Systems Expands Partnership with Eilean Therapeutics and Joins Its Best-in-Class PTPN2 Inhibitor Program

/PRNewswire/ -- Expert Systems, a leader in AI-enabled drug discovery, announces the expansion of the collaboration with Eilean Therapeutics as it joins its...

Australia , United-states , Rockville , Western-australia , America , Johnc-byrd , Bill-farley , Expert-systems-inc , Eilean-therapeutics , Inhibitor-program , Ness-therapeutics-inc , Expert-systems

EILEAN THERAPEUTICS APPROVED TO INITIATE FIRST PATIENT TRIAL WITH BALAMENIB (ZE63-0302), A SELECTIVE BEST-IN-CLASS MENIN INHIBITOR

/PRNewswire/ -- Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule...

Dover , Tasmania , Australia , Australian , Johnc-byrd , Amy-burd , Expert-systems-inc , Prnewswire-eilean-therapeutics , Eilean-therapeutics-australia-pty-ltd , Human-research-ethics-committee , Australian-therapeutics-goods-administration , Eilean-therapeutics

Expert Systems Celebrates Completion of Single Dose Studies and Start of Multiple Human Dosing for Lomonitinib, a Selective Pan-FLT3/IRAK4 Inhibitor, Achieved in Just 3 Years

Expert Systems Celebrates Completion of Single Dose Studies and Start of Multiple Human Dosing for Lomonitinib, a Selective Pan-FLT3/IRAK4 Inhibitor, Achieved in Just 3 Years
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United-states , Rockville , Western-australia , Australia , America , Johnc-byrd , Bill-farley , Eilean-therapeutics , Expert-systems-inc , Systems-celebrates-completion , Single-dose-studies , Multiple-human-dosing

Expert Systems Celebrates Accelerated Start of Human Dosing for Eiletoclax, a Selective BCL2 Inhibitor, Achieved in Just 3 Years

/PRNewswire/ -- Expert Systems, a leader in AI-enabled drug discovery, proudly announces a significant achievement in collaboration with Eilean Therapeutics...

Rockville , Western-australia , Australia , United-states , America , Bill-farley , Johnc-byrd , Expert-systems-inc , Eilean-therapeutics , Human-research-ethics-committee , Torrey-pines-investment , Expert-system

Expert Systems Celebrates Accelerated Start of Human Dosing for Eiletoclax, a Selective BCL2 Inhibitor, Achieved in Just 3 Years

Expert Systems Celebrates Accelerated Start of Human Dosing for Eiletoclax, a Selective BCL2 Inhibitor, Achieved in Just 3 Years
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Rockville , Western-australia , Australia , United-states , America , Johnc-byrd , Bill-farley , Human-research-ethics-committee , Eilean-therapeutics , Expert-systems-inc , Torrey-pines-investment , Expert-system

EILEAN THERAPEUTICS INITIATES FIRST IN HUMAN TRIAL WITH EILETOCLAX, A SELECTIVE BCL2 INHIBITOR WITH LIMITED IMMUNE SUPPRESSION AND IMPROVED SAFETY COMPARED TO VENETOCLAX AND VENETOCLAX-LIKE MOLECULES

/PRNewswire/ -- Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule...

Australia , Dover , Tasmania , Johnc-byrd , Human-research-ethics-committee , Expert-systems-inc , Prnewswire-eilean-therapeutics , Eilean-therapeutics , Iain-dukes , Chief-executive-officer , Torrey-pines-investment

EILEAN THERAPEUTICS COMPLETES SINGLE DOSE STUDIES AND INITIATES MULTIPLE DOSING OF HEALTHY VOLUNTEERS WITH LOMONITINIB, A SELECTIVE PAN-FLT3/IRAK4 INHIBITOR

EILEAN THERAPEUTICS COMPLETES SINGLE DOSE STUDIES AND INITIATES MULTIPLE DOSING OF HEALTHY VOLUNTEERS WITH LOMONITINIB, A SELECTIVE PAN-FLT3/IRAK4 INHIBITOR
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Amy-burd , Expert-systems-inc , Prnewswire-eilean-therapeutics , Eilean-therapeutics , Iain-dukes , Chief-executive-officer , Torrey-pines-investment , Expert-systems ,

ChemDiv Presented Non-Clinical Summary Data for The Best-in-Class Selective FLT3 Clinical Candidate at the 65th ASH Annual Meeting and Exposition with Its Partners and Sponsors

ChemDiv Presented Non-Clinical Summary Data for The Best-in-Class Selective FLT3 Clinical Candidate at the 65th ASH Annual Meeting and Exposition with Its Partners and Sponsors
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

Ohio , United-states , Dover , Delaware , San-diego , California , Australia , University-of-cincinnati , America , Ronald-demuth , John-byrd , Prnewswire-chemdiv-inc

Investigators from John Byrd's Lab at University of Cincinnati Presented Non-Clinical Summary Data for The Best-in-Class Selective BCL2 Inhibitor Clinical Candidate Developed by Eilean Therapeutics in

Investigators from John Byrd's Lab at University of Cincinnati Presented Non-Clinical Summary Data for The Best-in-Class Selective BCL2 Inhibitor Clinical Candidate Developed by Eilean Therapeutics in
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

University-of-cincinnati , Ohio , United-states , Australia , San-diego , California , Dover , Delaware , America , John-byrd , Eilean-therapeutics , Expert-systems-inc